Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis
of Alzheimer disease (AD). This knowledge has been translated into new therapeutic …

Objective Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD)
in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods Amyloid‐β 1 to …

Background Disease-modifying treatment strategies for Alzheimer's disease have led to an
urgent need for biomarkers to identify the disease at a very early stage. Here, we assess the …

The First Key Symposium was held in Stockholm, Sweden, 2–5 September 2003. The aim
of the symposium was to integrate clinical and epidemiological perspectives on the topic of …

Background The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and
phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient …

In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic
recommendations for the preclinical, mild cognitive impairment, and dementia stages of …

Alzheimer's disease is the most common cause of dementia. Research advances have enabled
detailed understanding of the molecular pathogenesis of the hallmarks of the disease—…

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Early diagnosis of Alzheimer's disease (AD) is needed to initiate symptomatic treatment with
acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at …

Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …